XTalks

NOVEMBER 9, 2021

Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. Over the last year, researchers have been studying the effectiveness of RNA-based pesticides, and there are already a handful of sprays in the works.

RNA 98

RNA Gene Scientist Protein 98

Pharmaceutical Technology

APRIL 20, 2023

Targovax has unveiled plans to rebrand as Circio , reflecting its strategic shift to focus on expediting the development of its innovative circular RNA (circRNA) platform. Initially reported in 2011, CircRNA is a naturally occurring class of RNA.

Gene Therapy 240

Gene Therapy RNA Gene Development 240

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

pharmaphorum

MAY 11, 2021

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body.

RNA 98

RNA Drugs Protein Immune Response 98

Pharma Mirror

APRIL 21, 2024

With the rapid development of biotechnology and molecular medicine, the introduction of mRNA as a vaccine or therapeutic agent enables the production of almost any desired functional protein/peptide within the human body.

In-Vitro 130

In-Vitro Drugs Genetic Disease RNA 130

Pharmaceutical Technology

FEBRUARY 1, 2023

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

Vaccination 162

Vaccination Vaccine Antibody Development 162

STAT News

JULY 19, 2022

An expert panel that advises the Centers for Disease Control and Prevention on vaccine policy voted Tuesday to recommend use of Novavax’s Covid-19 vaccine — an achievement a long time in the making for the Gaithersburg, Md.-based based company.

Vaccination 98

Vaccination Vaccine RNA Branding 98

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These viruses carry the genetic information to synthesise an RNA-dependent RNA polymerase.

RNA 240

RNA Genetics Vaccination Vaccine 240

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. “But it may be; and if it doesn’t other novel vaccines with similar benefits may well take on this role.”

Protein 126

Protein Vaccination Vaccine Immune Response 126

XTalks

JUNE 20, 2022

Alnylam Pharmaceuticals, a leading RNA interference (RNAi) therapeutics biopharmaceutical company, announced it received approval from the US Food and Drug Administration (FDA) for its RNAi therapeutic Amvuttra (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (ATTR) amyloidosis in adults.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

SEPTEMBER 16, 2020

In May, Germany pledged to provide up to €750 million ($889 million) in funding to support vaccines against COVID-19, and the main recipients have now been revealed – BioNTech, CureVac and IDT Biologika – which are all German biotechs. Both of these vaccines are based on RNA and in phase 3 and phase 1 testing, respectively.

Vaccination 86

Vaccination Vaccine RNA Trials 86

XTalks

JUNE 5, 2023

Pfizer has announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has received approval from the US Food and Drug Administration (FDA). Abrysvo, the bivalent RSV prefusion F (RSVpreF) vaccine, is intended for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

pharmaphorum

MAY 10, 2021

BioNTech has said it plans to set up a regional base and new manufacturing site in Singapore so that the biotech can keep pace with demand for its mRNA-based coronavirus vaccine and pipeline products in other disease areas. It’s an important milestone for the company, which established a US headquarters in Cambridge, Massachusetts last year.

Manufacturing 129

Manufacturing Vaccination Vaccine Protein 129

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. mRNA’s potential for rapid vaccine delivery.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

Delveinsight

AUGUST 26, 2021

Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. This system is designed to deliver RNA editing technology or other payloads directly to particular body areas, such as the nervous system or muscle.

Vaccination 98

Vaccination Vaccine Gene Therapy RNA 98

Scienmag

FEBRUARY 21, 2022

Proteins need to interact in a complex manner for a so-called “messenger RNA” (mRNA) to be created in human cells from a precursor molecule. mRNA provides a blueprint for proteins; the first vaccines against the coronavirus are also based on mRNAs.

Protein 55

Protein RNA Vaccination Vaccine 55

pharmaphorum

NOVEMBER 9, 2020

As the death toll from COVID19 inexorably mounts, Pfizer and BioNTech have announced that their COVID-19 vaccine candidate is more than 90% effective at countering the disease in an interim analysis. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule.

Vaccination 98

Vaccination Vaccine Clinical Trials Clinical Trials 98

pharmaphorum

JANUARY 10, 2022

The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

Pharmaceutical Technology

JUNE 6, 2023

The therapeutic candidate consists of messenger RNA (mRNA) encoding for relaxin. It is developed based on messenger RNA expression and N2GL formulation platform. Moderna Overview Moderna is a biotechnology company that focuses on the development of messenger RNA therapeutics and vaccines.

RNA 100

RNA Protein Antibody Vaccination 100

XTalks

OCTOBER 21, 2020

The answer may lie in the genetic code of the virus, which scientists at Duke University have found contains several silent mutations that affect protein folding. The researchers focused on the spike proteins that protrude from the surface of the coronavirus, which are responsible for viral attachment and entry into host cells.

RNA 98

RNA Protein Genome Genomics 98

pharmaphorum

APRIL 12, 2021

The coronavirus variant discovered in South Africa may evade Pfizer/BioNTech’s vaccine, according to a real-world data study conducted in Israel. But among patients who had received two doses of the vaccine, the variant’s prevalence was eight times higher than in unvaccinated people – 5.4% Known as variant B.1.351, versus 0.7%.

Vaccination 83

Vaccination Vaccine RNA Protein 83

XTalks

DECEMBER 22, 2021

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. The power of its real-world application was demonstrated by the resounding success of the mRNA COVID-19 vaccines. RNA in the Making.

Life Science 98

Life Science RNA Vaccination Vaccine 98

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology. Antibodies cover the pathogen of the virus and neutralise it.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

pharmaphorum

NOVEMBER 17, 2020

Pfizer has begun a pilot delivery programme in the US for its experimental COVID-19 vaccine, as the company seeks to overcome logistical challenges caused by its ultra-cold storage requirements. The vaccine developed in partnership with Germany’s BioNTech has been shown to be 90% effective in clinical trials.

Vaccination 77

Vaccination Vaccine RNA Clinical Trials 77

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

pharmaphorum

FEBRUARY 19, 2021

billion doses of its COVID-19 vaccine to the COVAX global initiative led by Gavi, the vaccine alliance, which aims to ensure fair access across the globe. There are growing concerns about the lack of COVID vaccines available to poorer countries. billion COVID shots to global vaccine drive appeared first on.

Vaccination 80

Vaccination Vaccine Manufacturing RNA 80

Camargo

JULY 27, 2021

Gene therapy, which was in its infancy around 30 years ago, is now becoming a more prominent treatment method in many therapeutic areas, from personalized therapy to mass vaccinations against COVID-19. For example, it is beneficial to administer RNA treatments for some lung diseases directly to the disease site through inhalation.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

pharmaphorum

AUGUST 31, 2021

Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. The post ‘Endless RNA’ startup Laronde raises $440m to fuel pipeline appeared first on.

RNA 52

RNA Protein Immune Response Medicine 52

pharmaphorum

NOVEMBER 23, 2020

AstraZeneca is preparing to file its COVID-19 vaccine with regulators after phase 3 trial results showed it is up to 90% effective. AZ made the announcemen t as the UK regulator reportedly gears up to make a decision on the rival vaccine from Pfizer and BioNTech, ahead of counterparts in the US and Europe.

Vaccination 105

Vaccination Vaccine Regulation Protein 105

pharmaphorum

DECEMBER 13, 2021

It started with two Covid-19 vaccines – 2021 is the year interest in mRNA therapeutics boomed, reports Katrina Megget. The Covid-19 pandemic showed what could be done with resources and collaboration to accelerate the development of vaccines. There are multiple other mRNA vaccines that are being developed.

RNA 105

RNA Vaccination Vaccine Development 105

pharmaphorum

JULY 6, 2021

Nina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic and how an integrated approach with vaccines could help normal life resume. PCR tests screen for the presence of viral RNA from a swab, detecting whether an individual is currently infected.

Antibody 111

Antibody Immune Response Protein Vaccination 111

pharmaphorum

MARCH 11, 2022

After a period where vaccine development had fallen away, suddenly it is back in the limelight. However, for those individuals working on vaccine development, the pandemic has proven to be a validation of the important work being carried out in the field. billion from its vaccine in 2021. The ‘poor relation’.

Vaccination 81

Vaccination Vaccine Development Manufacturing 81

pharmaphorum

NOVEMBER 10, 2021

After being hailed as a triumph of public-private drug development, Moderna’s partnership with the US government on its COVID-19 vaccine looks like it may descend into acrimony. The patent has been filed but not yet awarded.

Vaccination 105

Vaccination Vaccine Scientist Protein 105

pharmaphorum

JANUARY 26, 2023

The combination of advanced long- and short-read genomic sequencing technologies holds great promise for precision oncology, and in the development of mRNA vaccines for certain cancers. Just one mutation can lead to a complete change in protein formation. So, when it comes to proteomics, accuracy is vital.

Genome 129

Genome Genomics Genome Project Genetics 129

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases.

Vaccination 52

Vaccination Vaccine DNA Protein 52